How RadioNab Works
RadioNabs® Revolutionizes Targeted Radiotherapy with Alpaca-Derived Antibodies
The science behind RadioNab®
Alpacas Antibodies
The Andes Mountains provide the natural habitat for South American camelids, including alpacas. We are privileged to access an alpaca platform in Chile, situated in a region offering ideal geographic and environmental conditions for maintaining healthy, naturally raised alpacas.
Our innovative platform employs a unique and efficient method for the rapid generation of nanobodies with exceptionally high affinities. These alpaca-derived nanobodies are unparalleled in their specificity and stability, making them uniquely suited for cutting-edge applications in diagnostics and therapeutic development.
RadioNabs®
Radioligand therapy (RLT) has been proven to extend survival, even in metastatic patients. The leading drug in the field, 177Lu-PSMA-617 (Pluvicto® by Novartis), is approved for treating metastatic castration-resistant prostate cancer (mCRPC) that expresses prostate-specific membrane antigen (PSMA). It combines a targeting ligand (PSMA-617) with Lutetium-177 (¹⁷⁷Lu), a beta-emitting radionuclide, to selectively destroy cancer cells while sparing healthy tissue.
Clinical studies show that men treated with Pluvicto plus standard therapy lived a median of 15.3 months, compared to 11.3 months with standard therapy alone. However, small molecules have limited interaction surfaces, and discovering high-affinity binders is often slow and labor-intensive.
This is where RadioNabs® come in—leveraging Nanobody-based “magic bullets” derived from the alpaca immune system. These innovative binders offer a faster, more effective approach to expanding the potential of radioligand therapies, opening new possibilities for cancer treatment.
Theranostics Capability
Integrating diagnostics and therapy into a single platform, enabling real-time tracking of treatment effectiveness.
Through the combination advanced molecular science with state-of-the-art radiotherapy, RadioNab opens new frontiers in precision oncology, offering hope for patients and redefining cancer care.
Our Pipeline
Let's share our challenges